Milestones :: Perspectives :: Research
New global partnership launched to fight future pandemics
The Government will launch a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.
Updated: 20 April 2021
:: International Pandemic Preparedness Partnership (PPP) will support PM’s target to slash the time to develop vaccines for new diseases to 100 days
:: Partnership will be chaired by UK Chief Scientific Adviser Sir Patrick Vallance and will report to leaders at June’s G7 Summit
:: New £16m funding to Coalition for Epidemic Preparedness Innovations (CEPI) will also support global vaccine supply and development
The [U.K.] Government launched a new Pandemic Preparedness Partnership (PPP) to save lives from future diseases and prevent another global pandemic.
The PPP will advise the UK G7 Presidency on how to meet the Prime Minister’s ambition to slash the time to develop and deploy high quality vaccines for new diseases from 300 to 100 days, backed by additional funding to support CEPI’s work on global vaccine supply. It will be chaired by the Government’s Chief Scientific Adviser Sir Patrick Vallance.
The public-private partnership will bring together industry, international organisations and leading experts. They will provide recommendations for delivering ambitious targets to more quickly develop vaccines, therapeutics and diagnostics through greater global co-operation on research and development, manufacturing, clinical trials and data-sharing.
The £16 million investment will fund global vaccine manufacturing capacity and critical research and development to rapidly respond to the threat of new strains, supporting the development of new variant-specific vaccines. CEPI’s work to coordinate research, development and manufacturing of vaccines will aid efforts to have millions of doses of vaccine available for emergency use 100 days from a variant of concern being identified.
The PPP is meeting formally for the first time today at a two day virtual Pandemic Preparedness Partnership Conference, taking place under the UK’s Presidency of the G7…
…There 20 members of the PPP include WHO Vaccines Envoy Sir Andrew Witty, Professor of Medicine at the University of Oxford & member of the Bill & Melinda Gates Foundation Scientific Advisory Committee, Sir John Bell, Managing Director of the COVAX Facility Gavi, Aurelia Nguyen, and Chief Executive Officer of the Coalition for Epidemic Preparedness Innovations (CEPI) Richard Hatchett.
Industry members include representatives from leading vaccine developers and life sciences companies such as Head of Global Drug Development and Chief Medical Officer at Novartis, John Tsai, Executive Vice President Biopharmaceuticals R&D at AstraZeneca, Sir Mene Pangalos, Chief Scientific Officer at Pfizer, Mikael Dolsten and Chief Scientific Officer at Johnsen & Johnsen, Paul Stoffels.
These experts will be joined by scientific advisers from our G7 partners, who will play a key role in shaping the recommendations into an actionable roadmap over the next two months through a series of meetings ahead of the June Leader’s Summit…
Full list of PPP Steering Group members:
Chair – Sir Patrick Vallance – UK Government Chief Scientific Adviser
Sir Andrew Witty – CEO, United Health Group
Sir John Bell – Regius Professor of Medicine, University of Oxford and member of the Bill & Melinda Gates Foundation Scientific Advisory Committee
Martin Landray – Professor of Medicine and Epidemiology, University of Oxford.
Dame Anne Johnson – Professor of Infectious Disease Epidemiology UCL
Lord Jim O’Neill – Former Chairman of Goldman Sachs Asset Management & Former Commercial Secretary to the Treasury
Baroness Minouche Shafik – Director LSE and former Deputy Governor of the Bank of England
Aurelia Nguyen – Managing Director Office of the COVAX Facility, Gavi
Sir Jeremy Farrar – Director Wellcome Trust & Chair of the Scientific Advisory Group of the WHO R&D Blueprint.
John-Arne Rottingen – Co-chair ACT-A, member of the G20 High Level Independent Panel (HLIP) on financing for pandemic preparedness and response & ambassador for Global Health, Norwegian Ministry of Foreign Affairs.
Peter Sands – Executive Director – Global Fund
Richard Hatchett – Chief Executive Officer CEPI
Sergio Carmona – Acting Chief Executive Officer and Chief Medical Officer FIND
Soumya Swaminathan – Chief Scientist WHO
John Tsai – Head of Global Drug Development and Chief Medical Officer, Novartis
Sir Mene Pangalos – Executive Vice President Biopharmaceuticals R&D, AstraZeneca
Mikael Dolsten – Chief Scientific Officer, Pfizer
Paul Stoffels – Vice Chairman and Chief Scientific Officer, J&J
Roger Connor – President Global Vaccines, GSK
June Raine – Chief Executive, MHRA